<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005983</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067971</org_study_id>
    <secondary_id>U10CA032102</secondary_id>
    <secondary_id>S9927</secondary_id>
    <secondary_id>S9927</secondary_id>
    <secondary_id>CAN-NCIC-MA25</secondary_id>
    <secondary_id>CLB-49910</secondary_id>
    <secondary_id>S9927</secondary_id>
    <secondary_id>S9927</secondary_id>
    <secondary_id>S9927</secondary_id>
    <secondary_id>RTOG-9915</secondary_id>
    <nct_id>NCT00005983</nct_id>
  </id_info>
  <brief_title>S9927 Radiation Therapy After Surgery, Chemotherapy, and/or Hormone Therapy in Stage II Breast Cancer</brief_title>
  <official_title>Randomized Trial of Post-Mastectomy Radiotherapy in Stage II Breast Cancer in Women With One to Three Positive Axillary Nodes Phase III</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southwest Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>North Central Cancer Treatment Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>American College of Surgeons</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eastern Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Radiation Therapy Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer and Leukemia Group B</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NSABP Foundation Inc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Southwest Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet&#xD;
      known whether mastectomy, chemotherapy, and/or hormone therapy are more effective with or&#xD;
      without radiation therapy in treating breast cancer.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to compare the effectiveness of mastectomy, chemotherapy,&#xD;
      and/or hormone therapy with or without radiation therapy in treating women who have stage II&#xD;
      breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare overall and disease-free survival in women with stage II breast cancer with one&#xD;
           to three positive nodes treated with radiotherapy vs observation only after mastectomy&#xD;
           and adjuvant chemotherapy and/or hormonal therapy.&#xD;
&#xD;
        -  Compare local regional control in patients treated with these regimens.&#xD;
&#xD;
        -  Assess the potential toxic effects of radiotherapy in this patient population.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to prior&#xD;
      systemic hormonal therapy (chemotherapy with or without hormonal therapy vs hormonal therapy&#xD;
      alone), prior taxane exposure (yes vs no), and duration of chemotherapy (no chemotherapy vs&#xD;
      less than 3 months vs 3-5 months vs 6 months or more). Patients are randomized to one of two&#xD;
      treatment arms.&#xD;
&#xD;
        -  Arm I: Patients undergo radiotherapy 5 days a week for 5 weeks.&#xD;
&#xD;
        -  Arm II: Patients are observed for disease progression. Patients are followed every 6&#xD;
           months for 2 years and then annually for 15 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 2,500 patients (1,250 per treatment arm) will be accrued for&#xD;
      this study within 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    due to lack of accrual&#xD;
  </why_stopped>
  <start_date>June 2000</start_date>
  <completion_date type="Actual">March 2005</completion_date>
  <primary_completion_date type="Actual">March 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">98</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>surgery followed by observation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>surgery followed by RT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Surgery followed by radiation therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <arm_group_label>surgery followed by RT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>surgery</intervention_name>
    <description>surgery</description>
    <arm_group_label>surgery</arm_group_label>
    <arm_group_label>surgery followed by RT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed stage II adenocarcinoma of the breast (T1-2, N1, M0)&#xD;
&#xD;
               -  Primary tumor no greater than 5 cm&#xD;
&#xD;
               -  At least 1 but no more than 3 positive axillary lymph nodes&#xD;
&#xD;
               -  Nodes cannot be positive solely by cytokeratin staining&#xD;
&#xD;
               -  No apocrine, adenocystic, or squamous cell carcinomas or sarcomas of the breast&#xD;
&#xD;
               -  No bilateral breast cancer&#xD;
&#xD;
               -  No active local regional disease&#xD;
&#xD;
          -  Must have undergone a modified radical mastectomy with a level I and II with or&#xD;
             without a level III axillary dissection (at least 10 nodes examined) within the past 8&#xD;
             months&#xD;
&#xD;
               -  Surgical margins negative for invasive and noninvasive ductal carcinoma&#xD;
&#xD;
               -  No gross extracapsular disease or residual disease in the axilla&#xD;
&#xD;
               -  Microscopic extracapsular extension allowed&#xD;
&#xD;
          -  No mastectomy after local failure following lumpectomy&#xD;
&#xD;
          -  Must have received adjuvant chemotherapy and/or hormonal therapy after mastectomy&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  21 and over&#xD;
&#xD;
        Sex:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status:&#xD;
&#xD;
          -  Pre- or post-menopausal&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Zubrod 0-1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other prior malignancy within the past 5 years except adequately treated basal cell&#xD;
             or squamous cell skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No serious medical or psychiatric illness that would preclude study compliance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No prior trastuzumab (Herceptin)&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No more than 6 weeks since prior adjuvant chemotherapy&#xD;
&#xD;
          -  No other prior chemotherapy&#xD;
&#xD;
          -  Concurrent adjuvant chemotherapy allowed&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Concurrent adjuvant hormonal therapy allowed&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior chest wall or nodal radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Breast reconstruction allowed&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Concurrent registration on another adjuvant chemotherapy or hormonal therapy study is&#xD;
             allowed&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lori J. Pierce, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Michigan Rogel Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael G. Haddock, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen B. Edge, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric A. Strom, MD, FACR</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lawrence J. Solin, MD, FACR</last_name>
    <role>Study Chair</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lawrence B. Marks, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Timothy J. Whelan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Margaret and Charles Juravinski Cancer Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Melvin Deutsch, MD</last_name>
    <role>Study Chair</role>
    <affiliation>UPMC Cancer Center at UPMC Presbyterian</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Care Ontario-Hamilton Regional Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>July 5, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 22, 2013</last_update_submitted>
  <last_update_submitted_qc>January 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage II breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

